The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
BUSINESS
AZ Japan Sees Combo Holding Promise in Immuno-Oncology Race, Set to Triple Oncology Sales in 5 Years
Dave Fredrickson, the new Japan chief of AstraZeneca, expressed his confidence on October 25 that his company could catch up with rivals in the immuno-oncology (IO) space by capitalizing on its combination therapy of two internally developed IO compounds. “We…
To read the full story
Related Article
- AZ Boosting Field Force Specialization with Move to Business Units: Japan Chief
April 19, 2017
- Dave Fredrickson Tapped as Next Chief of AstraZeneca Japan
June 13, 2016
- AZ Set to Double Japan Sales by 2020 on Cancer Meds, No Patent Cliff in Sight: Local Pres. Baertschi
May 11, 2016
- AZ Eyes Low Single-Digit Growth over Coming Years in Japan: Pres. Baertschi
November 16, 2015
BUSINESS
- Astellas Snags Rights to Sangamo’s AVV Capsid for Neurological Diseases
December 20, 2024
- Xocova to Be Re-Filed in South Korea with Additional Data
December 20, 2024
- JCR Commences PIII Study for Once-Weekly Growth Hormone Therapy
December 20, 2024
- Insomnia Med Quviviq Now Available in Japan: Nxera/Shionogi
December 20, 2024
- PeptiDream Gets Milestone from Novartis on PI Launch
December 20, 2024
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…